Every 8-K that Charles River Laboratories International, Inc. (CRL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.
Charles River Laboratories International, Inc. reaffirmed its 2026 guidance at Investor Day, saying revenue and non-GAAP earnings per share are expected at the upper ends of prior ranges. The guidance lists organic revenue growth at the upper end of 0%–1%, non-GAAP operating margin of 21.0%–21.3%, and non-GAAP earnings per share at the upper end of $11.15–$11.45.
Its Pathway to Purpose strategy focuses on productivity and efficiency, scientific portfolio investments, and a customized client approach. For 2027–2030, its targets are 5%–7% organic revenue CAGR, approximately 24% non-GAAP operating margin, and low-double-digit non-GAAP earnings-per-share CAGR. The company expects its Create the Future program to generate over $300 million in cumulative savings from 2027 through 2030; bioanalysis revenue is expected to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The Apollo platform serves more than 18,000 client users. The 2030 targets exclude future acquisitions and divestitures and are not projections or financial guidance; they are subject to significant uncertainties and contingencies and management assumptions that may change.
Charles River Laboratories International, Inc. reported second‑quarter 2026 revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, while organic revenue edged up 0.1%. GAAP results swung to a small net loss of $(1.5) million, or $(0.03) per share, primarily due to a $63.7 million loss on the divestiture of its CDMO and Cell Solutions businesses.
On a non‑GAAP basis, operating margin was 20.5% versus 22.1% and net income declined 5.0% to $146.2 million, with diluted EPS of $3.02 compared with $3.12 in the prior‑year quarter. Segment results were mixed: RMS revenue was $209.5 million with organic revenue down 1.4%, DSA revenue was $606.5 million with organic growth of 0.2%, and Manufacturing revenue was $188.1 million, down 6.3% reported but up 1.3% organically.
The company repurchased $100.0 million of stock in the quarter and $300.0 million year‑to‑date, leaving $700.0 million under its $1.0 billion authorization. For 2026, it raised organic revenue growth guidance to 0.0%–1.0% and non‑GAAP EPS to $11.15–$11.45, while lowering GAAP EPS guidance to $3.05–$3.35 to incorporate divestiture‑related losses.
Charles River Laboratories International, Inc. reported the results of its 2026 annual meeting of shareholders. Twelve directors were elected to serve until the 2027 annual meeting, each receiving more votes for than against, with broker non-votes recorded on each director proposal.
Shareholders approved, on an advisory, non-binding basis, the compensation of the company’s named executive officers and approved the new 2026 Long-Term Incentive Plan, which had previously been adopted by the board subject to shareholder approval. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2026.
Charles River Laboratories reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier, but revenue declined 1.5% on an organic basis once currency and divestitures are excluded. GAAP results swung to a net loss of $14.8 million, or $(0.30) per share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture.
On a non-GAAP basis, operating margin fell to 16.3% from 19.1%, and net income decreased 14.6% to $101.7 million, or $2.06 per diluted share, versus $2.34 a year ago, largely from higher DSA study costs, unfavorable RMS mix, and higher stock-based compensation. Segment performance was mixed, with Manufacturing organic revenue up 2.9% and RMS and DSA down 5.5% and 1.4%, respectively.
The company completed the sale of its CDMO and Cell Solutions businesses on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026 to sharpen focus on core drug development testing. It also repurchased 1.1 million shares for $200 million, leaving $800 million under its $1.0 billion authorization. Management reaffirmed 2026 organic revenue and non-GAAP EPS guidance of $10.80–$11.30, while trimming reported revenue growth by about 50 basis points for foreign exchange and updating GAAP EPS guidance to $5.35–$5.85.
Charles River Laboratories plans two sizable divestitures and has revised its 2026 outlook to reflect the impact. The company signed a definitive agreement to sell its CDMO and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments, after those units generated $143 million of revenue in 2025. It also agreed to sell certain European Discovery Services assets to IQVIA for about $145 million in cash plus up to $10 million more.
Together, the planned divestitures are expected to reduce 2026 reported revenue by slightly more than 5%, shifting guidance to a reported decline of 5.0% to 3.5%. At the same time, management expects at least 100 basis points of incremental non-GAAP operating margin improvement in 2026 and about $0.10 of non-GAAP EPS accretion for the partial year, raising its non-GAAP EPS guidance range to $10.80–$11.30.
Charles River Laboratories International, Inc. appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer. He is expected to start on April 6, 2026, succeeding interim CFO Michael G. Knell, who will continue as Corporate Senior Vice President and Chief Accounting Officer.
Mr. Coleman, 58, brings more than 30 years of financial and operational experience, including senior roles in the healthcare sector. He most recently served as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., and previously held CFO and operational leadership positions at DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation.
Charles River Laboratories International, Inc. reported slightly lower 2025 results and issued a cautious 2026 outlook. Fourth-quarter 2025 revenue was $994.2 million, down 0.8% year over year, with organic revenue down 2.6% as softness in Discovery and Safety Assessment and Manufacturing offset growth in some research model services.
The company posted a GAAP net loss of $276.6 million for the quarter, or $(5.62) per share, driven largely by $211.0 million of intangible asset impairments and $165.0 million of goodwill impairment in its Biologics Solutions and Cell Solutions operations. On a non-GAAP basis, Q4 diluted EPS was $2.39, down from $2.66. For full-year 2025, revenue was $4.02 billion, down 0.9%, with GAAP diluted loss per share of $(2.91) versus earnings of $0.20 in 2024, while non-GAAP diluted EPS slipped to $10.28 from $10.32.
Management highlighted improved late-2025 bookings in Discovery and Safety Assessment and issued 2026 guidance calling for reported revenue growth of at least flat to 1.5%, organic revenue ranging from a 1.0% decline to flat, and non-GAAP EPS between $10.70 and $11.20, reflecting expected cost savings, contribution from the K.F. (Cambodia) Ltd. asset acquisition, and a lower tax rate.
Charles River Laboratories International outlined improving demand and strategic moves ahead of a major healthcare conference. The company reported that demand in its Discovery and Safety Assessment (DSA) segment strengthened through the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter, meaning new DSA bookings exceeded revenue.
For 2026, the company expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated business and the DSA segment, with a cautious expectation of returning to revenue growth in the second half of 2026. Foreign exchange is expected to add 100–150 basis points to reported revenue growth, and incremental cost savings of more than $100M in 2026 are intended to offset cost inflation and support non-GAAP operating margin.
The company also plans two acquisitions: the assets of K.F. (Cambodia) Ltd. for about $510M, expected to be accretive to non-GAAP EPS by about $0.25 in 2026 and $0.60 in 2027, and the remaining 79% of PathoQuest SAS for €51.6M (about $60M), which is expected to generate $15–$20M of 2026 revenue but not materially affect 2026–2027 financial results.
Charles River Laboratories International, Inc. announced a planned leadership transition. On May 5, 2026, Chief Operating Officer Birgit Girshick will become Chief Executive Officer, succeeding James C. Foster, who will step down as CEO and Chair and is expected to remain a non-executive director. Lead Independent Director Dr. Martin Mackay is expected to become Chair of the Board on the same date.
Ms. Girshick’s compensation will be adjusted for her new role, with base salary set at $1,200,000 effective February 1, 2026, a target annual cash incentive equal to 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000, mostly in performance share units. In connection with a potential change in control, she would be eligible for severance equal to three times salary plus target bonus, three years of benefits, and outplacement services if terminated under specified conditions.
The Board size will increase from 11 to 12 directors as of the transition date to add Ms. Girshick, with consent from Elliott-affiliated funds under an existing cooperation agreement. Mr. Foster will receive restricted stock units with an underlying fair market value of $3,000,000, expected to be granted on March 2, 2026, vesting after two years, and is expected to receive standard non-executive director compensation thereafter.
Charles River Laboratories International, Inc. reported that demand indicators in its Discovery and Safety Assessment (DSA) segment are improving. At an investor presentation at the Evercore 8th Annual Healthcare Conference, management stated that DSA net book-to-bill has improved each month since the beginning of the third fiscal quarter of 2025. The company also noted that typical holiday seasonality in the fourth quarter and early January could affect near-term proposal and booking activity, but emphasized its encouragement with the positive momentum and upward trends observed since the middle of fiscal 2025.
Charles River Laboratories International, Inc. (CRL) announced the conclusion of an SEC investigation without an enforcement recommendation. The SEC’s Division of Enforcement informed the company that, based on the information available to it, it does not intend to recommend an enforcement action related to the company’s sourcing of non-human primates and related disclosures. The company’s Audit Committee also completed its own independent investigation into the same matters, reporting no material findings. This removes a regulatory overhang that had been disclosed since May 2023.
Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.
The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.
Charles River Laboratories International, Inc. filed an amendment to a prior report about its leadership change to add details on interim Chief Financial Officer Michael G. Knell’s compensation. Effective September 28, 2025, his annual base salary will be increased to $500,000. Starting October 1, 2025, he will also receive a $10,000 monthly cash payment during his term as interim Chief Financial Officer.
In addition, the Compensation Committee approved a one-time grant of restricted stock units with a grant value of $500,000 in the company’s common stock, to be granted on November 6, 2025. Half of these units will vest on the first anniversary of the grant date and the remaining half on the second anniversary, aligning part of his compensation with the company’s long‑term performance.
Charles River Laboratories International, Inc. reported that Chief Financial Officer Flavia H. Pease has informed the company she will resign as Corporate Executive Vice President and CFO, effective September 29, 2025. The company states that her decision is not due to any disagreements regarding financial statements, internal controls, operations, policies, or practices.
In connection with her departure, the Board has appointed Michael G. Knell, currently Corporate Senior Vice President and Chief Accounting Officer, to serve as interim Chief Financial Officer and principal financial officer, effective upon Ms. Pease’s departure and until a permanent successor is named. Mr. Knell has been with the company since 2017 and is a Certified Public Accountant with prior senior finance and audit experience. The company also issued a press release on September 16, 2025 announcing these changes.